Evofem Biosciences (EVFM) Competitors $0.01 +0.00 (+1.68%) As of 02:28 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EVFM vs. ENSC, MYNZ, SBFM, ACXP, PLRZ, PMCB, SNOA, CPHI, CERO, and SXTPShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Ensysce Biosciences (ENSC), Mainz Biomed (MYNZ), Sunshine Biopharma (SBFM), Acurx Pharmaceuticals (ACXP), Polyrizon (PLRZ), Nuvilex (PMCB), Sonoma Pharmaceuticals (SNOA), China Pharma (CPHI), CERo Therapeutics (CERO), and 60 Degrees Pharmaceuticals (SXTP). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. Its Competitors Ensysce Biosciences Mainz Biomed Sunshine Biopharma Acurx Pharmaceuticals Polyrizon Nuvilex Sonoma Pharmaceuticals China Pharma CERo Therapeutics 60 Degrees Pharmaceuticals Ensysce Biosciences (NASDAQ:ENSC) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Does the media prefer ENSC or EVFM? In the previous week, Ensysce Biosciences had 3 more articles in the media than Evofem Biosciences. MarketBeat recorded 3 mentions for Ensysce Biosciences and 0 mentions for Evofem Biosciences. Ensysce Biosciences' average media sentiment score of 0.63 beat Evofem Biosciences' score of 0.00 indicating that Ensysce Biosciences is being referred to more favorably in the media. Company Overall Sentiment Ensysce Biosciences Positive Evofem Biosciences Neutral Do analysts prefer ENSC or EVFM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, ENSC or EVFM? Ensysce Biosciences has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -1.13, indicating that its share price is 213% less volatile than the S&P 500. Do insiders and institutionals have more ownership in ENSC or EVFM? 5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 7.9% of Ensysce Biosciences shares are owned by insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is ENSC or EVFM more profitable? Evofem Biosciences has a net margin of -46.42% compared to Ensysce Biosciences' net margin of -88.76%. Evofem Biosciences' return on equity of -91.97% beat Ensysce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ensysce Biosciences-88.76% -167.23% -104.59% Evofem Biosciences -46.42%-91.97%-61.93% Which has stronger valuation and earnings, ENSC or EVFM? Evofem Biosciences has higher revenue and earnings than Ensysce Biosciences. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnsysce Biosciences$5.21M1.30-$7.99M-$4.03-0.57Evofem Biosciences$11.39M0.13$52.98M-$0.07-0.17 SummaryEnsysce Biosciences and Evofem Biosciences tied by winning 7 of the 14 factors compared between the two stocks. Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.53M$1.02B$6.02B$10.32BDividend YieldN/A4.84%5.66%4.69%P/E Ratio-0.021.2885.4226.63Price / Sales0.1330.66585.24179.51Price / CashN/A17.6438.3262.20Price / Book0.007.3212.756.58Net Income$52.98M-$7.96M$3.30B$275.87M7 Day PerformanceN/A33.88%1.42%-0.76%1 Month PerformanceN/A30.51%7.97%5.90%1 Year PerformanceN/A-6.03%80.23%32.58% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem Biosciences0.464 of 5 stars$0.01+1.7%N/A+8.2%$1.53M$11.39M-0.02120Gap UpHigh Trading VolumeENSCEnsysce Biosciences0.6817 of 5 stars$2.30-1.9%N/A-13.7%$6.89MN/A-0.5810News CoveragePositive NewsAnalyst ForecastMYNZMainz Biomed2.8461 of 5 stars$1.46flat$14.00+858.9%-89.9%$6.87M$893.99K-0.0230News CoverageGap UpSBFMSunshine Biopharma2.792 of 5 stars$1.47+1.4%$15.00+919.7%-44.3%$6.74M$36.34M-0.013News CoveragePositive NewsAnalyst ForecastGap UpACXPAcurx Pharmaceuticals2.7497 of 5 stars$4.17-2.6%$31.00+643.4%-81.9%$6.59MN/A-0.393News CoverageAnalyst ForecastGap DownPLRZPolyrizonN/A$1.10-2.7%N/AN/A$6.59MN/A0.00N/AAnalyst ForecastPMCBNuvilex0.6902 of 5 stars$0.95-3.6%N/A-42.3%$6.43MN/A-1.754Positive NewsAnalyst ForecastSNOASonoma Pharmaceuticals0.5441 of 5 stars$3.87-1.8%N/A+53.1%$6.35M$14.29M-1.57180News CoverageAnalyst ForecastGap DownCPHIChina PharmaN/A$1.94-1.3%N/A-91.7%$6.31M$4.40M0.00250CEROCERo Therapeutics3.0861 of 5 stars$5.13-2.3%$45.00+777.2%-98.0%$6.21MN/A0.008Analyst ForecastSXTP60 Degrees Pharmaceuticals2.4795 of 5 stars$1.48-3.6%$3.00+102.2%-69.2%$6.02M$641.41K-0.033News CoverageAnalyst ForecastGap Down Related Companies and Tools Related Companies Ensysce Biosciences Alternatives Mainz Biomed Alternatives Sunshine Biopharma Alternatives Acurx Pharmaceuticals Alternatives Polyrizon Alternatives Nuvilex Alternatives Sonoma Pharmaceuticals Alternatives China Pharma Alternatives CERo Therapeutics Alternatives 60 Degrees Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVFM) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredBig Oil Firm Stakes $1 Billion in Startup That Could Kill Big OilOn September 22, the unthinkable happened... One of the world's biggest oil producers poured $1 billion int...Stansberry Research | SponsoredBetter than Bitcoin?Bitcoin’s historic run may be ending — and Weiss Ratings’ Juan Villaverde, who’s nailed every major crypto bul...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
